The Effect of Luteinizing Hormone (LH) Supplementation Following Gonadotropin-releasing Hormone (GnRH) Antagonist Administration in Advanced Reproductive Ageing Women Undergoing IVF and Embryo Transfer (IVF/ET)

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01016210

Enrollment

Registered

2009-11-19

Start date

2010-02-28

Completion date

2013-04-30

Last updated

2014-01-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pregnancy Result Rape

Keywords

pregnancy, IVF

Brief summary

To explore whether recombinant LH (rLH) supplementation (Leuveris) to recombinant follicle stimulating hormone (rFSH) following GnRH antagonist treatment has an advantage in infertile women with advanced reproductive ageing undergoing IVF-ET.

Interventions

DRUGLeuveris

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

FEMALE

Age

25 Years to 45 Years

Healthy volunteers

Yes

Inclusion criteria

* female candidate to IVF * between 30-45 years old

Exclusion criteria

* not included for fertilization

Design outcomes

Primary

Measure	Time frame
Pregnancy rate	Starting February 2010

Secondary

Measure	Time frame
Fertilization rate	Starting February 2010 till April 2013

Countries

Israel

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026